1 August 2011 in The American Journal of the Medical Sciences
6 April 2012 in Clinical Cardiology
Background: This study was designed to assess the credibility of YouTube video information on acute myocardial infarction by exploring the relationship between accuracy of information on the topic, source of expertise, and perceived credibility of the message.Hypothesis: Health information videos in YouTube possess a diverse mix of information and can easily mislead online information seekers.Methods: The Web site http://www.YouTube.com was queried for the following search terms: “acute myocardial infarction,” “heart attack,” “acute coronary syndrome,” and “ST‐elevation myocardial infarction.” The resulting videos were categorized according to the source of the video and content was analyzed for discussion of different aspects of disease, ranging from pathophysiology to treatment.Results: Only 6% of videos touched upon all aspects of acute myocardial infarction. These were mostly from professional societies, were of long duration, and were among the least viewed. Videos that described personal experiences were “liked” or “disliked” most and had the majority of comments. Only 17% of the videos discussed the preventive aspects of the disease and stressed weight‐loss and exercise programs. Videos that stressed prevention were advertisements for specific weight‐loss programs (45%) and diet pills (30%). Very few videos stressed other risk factors. A large number of videos were irrelevant.Conclusions: YouTube is a popular platform across the globe for sharing video information, including videos related to health and disease. However, the information on this platform is not regulated and can easily mislead those seeking it. We suggest that authoritative videos should come from reputable sources such as professional societies and/or academic institutions and should provide unbiased and accurate information on all aspects of diseases like acute myocardial infarction. Clin. Cardiol. 2011 DOI: 10.1002/clc.21981The authors have no funding, financial relationships, or conflicts of interest to disclose.
22 May 2013 in Catheterization and Cardiovascular Interventions
1 March 2009 in Journal of Investigative Medicine
Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.
25 January 2012 in Clinical Cardiology